Conditions: Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 166
Healthy volunteers: no

Brief summary:
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.

Detailed description:

Arms:
arm 1: BI 655066 s.c. arm 2: BI 655066 s.c. arm 3: BI 655066 s.c. arm 4: Ustekinumab s.c.

Interventions: intervention 1: BI 655066 intervention 2: BI 655066 intervention 3: Ustekinumab intervention 4: BI 655066
Intervention descriptions: intervention 1: Medium dose intervention 2: High dose intervention 3: None intervention 4: Low dose

Protocol document: